Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis

doi:10.18773/austprescr.2024.038

Review

. 2024 Oct;47(5):158-159.

doi: 10.18773/austprescr.2024.038.

Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis

No authors listed

PMID: 39526079
PMCID: PMC11540911
DOI: 10.18773/austprescr.2024.038

Review

Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis

No authors listed. Aust Prescr. 2024 Oct.

. 2024 Oct;47(5):158-159.

doi: 10.18773/austprescr.2024.038.

PMID: 39526079
PMCID: PMC11540911
DOI: 10.18773/austprescr.2024.038

No abstract available

Keywords: ANCA; Tavneos; antineutrophil cytoplasmic antibody–associated vasculitis; avacopan.

PubMed Disclaimer

Similar articles

Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Alihosseini C, Kopelman H, Zaino M, Feldman SR. Alihosseini C, et al. Ann Pharmacother. 2023 Dec;57(12):1449-1454. doi: 10.1177/10600280231161592. Epub 2023 Mar 28. Ann Pharmacother. 2023. PMID: 36975183 Review.
The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
Strand V, Jayne DRW, Horomanski A, Yue H, Bekker P, Merkel PA; ADVOCATE Study Group. Strand V, et al. Lancet Rheumatol. 2023 Aug;5(8):e451-e460. doi: 10.1016/S2665-9913(23)00092-9. Epub 2023 Jul 24. Lancet Rheumatol. 2023. PMID: 38251577 Clinical Trial.
Avacopan, a Novel Competitive C5a Receptor Antagonist, for Severe Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
Nguyen ID, Sinnathamby ES, Mason J, Urban B, Neuchat EE, Wenger DM, Ahmadzadeh S, Shekoohi S, Kaye AD. Nguyen ID, et al. Clin Drug Investig. 2023 Aug;43(8):595-603. doi: 10.1007/s40261-023-01298-z. Epub 2023 Aug 18. Clin Drug Investig. 2023. PMID: 37596445 Review.
Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study.
Harigai M, Kaname S, Tamura N, Dobashi H, Kubono S, Yoshida T. Harigai M, et al. Mod Rheumatol. 2023 Mar 2;33(2):338-345. doi: 10.1093/mr/roac037. Mod Rheumatol. 2023. PMID: 35482532 Clinical Trial.
Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.
Patel NJ, Jayne DRW, Merkel PA, Bekker P, Zhang Y, Yue H, Stone JH. Patel NJ, et al. Lancet Rheumatol. 2023 Mar;5(3):e130-e138. doi: 10.1016/S2665-9913(23)00030-9. Epub 2023 Feb 20. Lancet Rheumatol. 2023. PMID: 38251609 Clinical Trial.

See all similar articles

References

1. Jarrot PA, Kaplanski G. Pathogenesis of ANCA-associated vasculitis: An update. Autoimmun Rev 2016;15:704-13. 10.1016/j.autrev.2016.03.007 - DOI - PubMed
1. Almaani S, Fussner LA, Brodsky S, Meara AS, Jayne D. ANCA-Associated Vasculitis: An Update. J Clin Med 2021;10:1446. 10.3390/jcm10071446 - DOI - PMC - PubMed
1. Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One 2016;11:e0164646. 10.1371/journal.pone.0164646 - DOI - PMC - PubMed
1. Therapeutic Goods Administration. Australian Public Assessment Report for Tavneos. Department of Health and Aged Care; 2023. https://www.tga.gov.au/resources/auspar/auspar-tavneos [cited 2024 Jul 26]
1. Jayne DR, Merkel PA, Schall TJ, Bekker P, Group AS, ADVOCATE Study Group . Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 2021;384:599-609. 10.1056/NEJMoa2023386 - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- PubMed Central

[1] Jarrot PA, Kaplanski G. Pathogenesis of ANCA-associated vasculitis: An update. Autoimmun Rev 2016;15:704-13. 10.1016/j.autrev.2016.03.007 - DOI - PubMed

[2] Jarrot PA, Kaplanski G. Pathogenesis of ANCA-associated vasculitis: An update. Autoimmun Rev 2016;15:704-13. 10.1016/j.autrev.2016.03.007 - DOI - PubMed

[3] Almaani S, Fussner LA, Brodsky S, Meara AS, Jayne D. ANCA-Associated Vasculitis: An Update. J Clin Med 2021;10:1446. 10.3390/jcm10071446 - DOI - PMC - PubMed

[4] Almaani S, Fussner LA, Brodsky S, Meara AS, Jayne D. ANCA-Associated Vasculitis: An Update. J Clin Med 2021;10:1446. 10.3390/jcm10071446 - DOI - PMC - PubMed

[5] Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One 2016;11:e0164646. 10.1371/journal.pone.0164646 - DOI - PMC - PubMed

[6] Bekker P, Dairaghi D, Seitz L, Leleti M, Wang Y, Ertl L, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One 2016;11:e0164646. 10.1371/journal.pone.0164646 - DOI - PMC - PubMed

[7] Therapeutic Goods Administration. Australian Public Assessment Report for Tavneos. Department of Health and Aged Care; 2023. https://www.tga.gov.au/resources/auspar/auspar-tavneos [cited 2024 Jul 26]

[8] Therapeutic Goods Administration. Australian Public Assessment Report for Tavneos. Department of Health and Aged Care; 2023. https://www.tga.gov.au/resources/auspar/auspar-tavneos [cited 2024 Jul 26]

[9] Jayne DR, Merkel PA, Schall TJ, Bekker P, Group AS, ADVOCATE Study Group . Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 2021;384:599-609. 10.1056/NEJMoa2023386 - DOI - PubMed

[10] Jayne DR, Merkel PA, Schall TJ, Bekker P, Group AS, ADVOCATE Study Group . Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 2021;384:599-609. 10.1056/NEJMoa2023386 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis

Avacopan for antineutrophil cytoplasmic antibody-associated vasculitis

Similar articles

References

Publication types

LinkOut - more resources

Full Text Sources